News

Filter

Current filters:

arGEN-X

Shire exercises option on candidates from arGEN-X collaboration

Shire exercises option on candidates from arGEN-X collaboration

11-12-2014

Ireland-headquartered drugmaker Shire has exercised the option to advance into preclinical development…

arGEN-XLicensingPharmaceuticalResearchShire

arGEN-X partners on ARGX-110 for Waldenstrom’s macroglobulinemia

arGEN-X partners on ARGX-110 for Waldenstrom’s macroglobulinemia

10-06-2014

Dutch/Belgian preclinical stage biotech company arGEN-X, has entered into a partnership with The Leukemia…

arGEN-XARGX-110BiotechnologyHematologyOncologyResearch

arGEN-X and Shire sign long term collaboration deal worth $20 million

arGEN-X and Shire sign long term collaboration deal worth $20 million

04-06-2014

Belgium-based preclinical stage biotech firm arGEN-X has entered into a long-term strategic alliance…

arGEN-XBiotechnologyBusiness FinanceEuropeHuman antibody discovery technologiesResearchShireShire Pharmaceuticals

arGEN-X R&D milestone triggers payment from Shire

19-09-2013

Belgium-based preclinical stage biotech firm arGEN-X has announced a key milestone in its SIMPLE Antibody…

arGEN-XBiotechnologyEuropeFinancialGenetics

Antibody technology from arGEN-X takes step forward

12-09-2013

Belgium-based preclinical stage biotech firm arGEN-X has generated potent antibody antagonists of Nav1.7…

arGEN-XBiotechnologyEuropeOncologyResearch

arGEN-X expands antibody deal with Shire; initiates ARGX-110 trial in cancer

08-01-2013

Netherlands and Belgium-based preclinical stage biotech firm arGEN-X, specialized in the discovery and…

arGEN-XARGX-110BiotechnologyLicensingOncologyRare diseasesResearchShire

Back to top